A Divalent PAMAM‐Based Matrix Metalloproteinase/Carbonic Anhydrase Inhibitor for the Treatment of Dry Eye Syndrome |
| |
| Authors: | V. Baldoneschi Prof. S. Burgalassi Dr. D. Vullo Dr. A. Akdemir Dr. E. Dragoni A. Louka M. Mamusa Dr. D. Monti Prof. D. Berti Prof. E. Novellino Prof. G. De Rosa Prof. C. T. Supuran Prof. C. Nativi |
| |
| Affiliation: | 1. Department of Chemistry “Ugo Schiff”, University of Florence, Sesto Fiorentino, Italy;2. Department of Pharmacy, University of Pisa, Pisa, Italy;3. Department of Pharmacy, Faculty of Pharmacy, Bezmialem Vakif University, Fatih, Istanbul, Turkey;4. CERM, University of Florence, Sesto Fiorentino, Italy;5. Department of Pharmacy, University of Napoli “Federico II” via Montesano 49, Napoli, Italy;6. NEUROFARBA Department, University of Florence, Sesto Fiorentino, Italy |
| |
| Abstract: | Synthetic sulfonamide derivatives are a class of potent matrix metalloproteinase inhibitors (MMPI) that have potential for the treatment of diseases related to uncontrolled expression of these enzymes. The lack of selectivity of the large majority of such inhibitors, leading to the inhibition of MMPs in tissues other than the targeted one, has dramatically reduced the therapeutic interest in MMPIs. The recent development of efficient drug delivery systems that allow the transportation of a selected drug to its site of action has opened the way to new perspectives in the use of MMPIs. Here, a PAMAM‐based divalent dendron with two sulfonamidic residues was synthesized. This nanomolar inhibitor binds to the catalytic domain of two MMPs as well as to the transmembrane human carbonic anhydrases (hCAs) XII, which is present in the eye and considered an antiglaucoma target. In the animal model of an experimental dry eye, no occurrence of dotted staining in eyes treated with our inhibitor was observed, indicating no symptoms of corneal desiccation. |
| |
| Keywords: | dendrimers drug delivery drug discovery inhibitors metalloproteins |
|
|
